GO:0070488 neutrophil aggregation: Adhesion, Signaling and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070488 neutrophil aggregation is defined as the adhesion of one neutrophil to one or more other neutrophils via adhesion molecules.
• Neutrophil aggregation is a distinct homotypic adhesion process that contributes to neutrophil swarming, immune complex clearance, and extracellular trap formation [1,4,8].
• Aggregated neutrophils can release extracellular vesicle storms and aggregated neutrophil extracellular traps that modulate inflammation and cytokine degradation [1,8].
• Pathogens such as Staphylococcus aureus and intracellular bacteria can evade or exploit aggregation through complement inhibition or type I interferon signaling [4,7].
• Key molecular players include adhesion molecules, P2Y14R, complement regulators, and granule proteins that influence aggregation and downstream effector functions [3,5,7].
• CRISPR knockout, knock-in, and overexpression models are essential to dissect the causal roles of specific genes in neutrophil aggregation [1,3,4].
Description
Neutrophil aggregation (GO:0070488) is a biological process defined as the adhesion of one neutrophil to one or more other neutrophils via adhesion molecules. This homotypic interaction is distinct from neutrophil adhesion to endothelium or platelets and represents a critical step in the coordinated behavior of neutrophils during inflammation and infection [1,4]. The process has been observed in diverse contexts, including systemic lupus erythematosus, where mesenchymal stromal cells induce neutrophil aggregation and extracellular vesicle storms, and in bacterial infections where pathogens modulate aggregation to evade killing [4,7]. Understanding neutrophil aggregation is therefore important for researchers studying innate immunity, autoimmunity, and thrombosis [1,3,8]. The QuickGO definition provides a precise framework: the adhesion of one neutrophil to one or more other neutrophils via adhesion molecules. This definition excludes heterotypic interactions and focuses on the molecular machinery that mediates neutrophil-neutrophil binding. Recent studies have begun to unravel the signaling pathways and adhesion molecules involved, revealing roles for purinergic receptors, complement regulators, and extracellular traps [3,7,8]. As the field moves toward therapeutic targeting of neutrophil-driven pathologies, robust experimental models are needed to test causality of candidate genes [1,4].
neutrophil aggregation At A Glance
| GO ID | GO:0070488 |
|---|---|
| GO term | neutrophil aggregation |
| Ontology | biological_process |
| Synonym | neutrocyte aggregation; neutrophilic leucocyte aggregation; neutrophilic leukocyte aggregation; neutrophil leucocyte aggregation; neutrophil leukocyte aggregation |
| Major function | Homotypic adhesion of neutrophils via adhesion molecules, contributing to immune complex clearance, swarming, and extracellular trap formation [1,4,8] |
| Related process | Neutrophil swarming, NET formation, and inflammation resolution [4,8] |
| Key triggers | Cytokines, pathogens, immune complexes, and mesenchymal stromal cells [1,2,7] |
| Pathological relevance | Systemic lupus erythematosus, venous thrombosis, bacterial evasion, and occlusive diseases [1,3,4,6] |
What Is GO:0070488?
Neutrophil aggregation is the process by which a neutrophil adheres to one or more other neutrophils through adhesion molecules. It is a homotypic cell-cell adhesion event that can be triggered by cytokines, pathogens, or immune complexes, and it leads to the formation of neutrophil clusters [1,2,4]. This process is distinct from neutrophil-platelet or neutrophil-endothelial adhesion and is often accompanied by the release of extracellular vesicles and neutrophil extracellular traps [1,8].
Why Is neutrophil aggregation Important in Cell Biology?
Neutrophil aggregation is important because it represents a fundamental mechanism by which neutrophils coordinate their effector functions during inflammation and infection [1,4]. Aggregated neutrophils can concentrate antimicrobial factors, form extracellular traps, and modulate cytokine and chemokine levels, thereby influencing the resolution or persistence of inflammation [1,8]. Dysregulated aggregation has been implicated in autoimmune diseases such as systemic lupus erythematosus and in thrombotic disorders [1,3]. Moreover, pathogens have evolved strategies to evade or exploit aggregation, highlighting its role in host-pathogen interactions [4,7]. Understanding the molecular basis of neutrophil aggregation is therefore essential for developing targeted therapies for inflammatory and infectious diseases [1,3,6].
• Neutrophil aggregation is a key step in neutrophil swarming, which amplifies the immune response at sites of infection or injury.
• Aggregated neutrophils release extracellular vesicle storms that can modulate immune cell function in systemic lupus erythematosus.
• Aggregated neutrophil extracellular traps degrade cytokines and chemokines, limiting inflammation.
• Pathogens such as Staphylococcus aureus can overcome complement-mediated inhibition of aggregation to evade neutrophil killing.
• Type I interferon signaling inhibits neutrophil swarming, promoting intracellular bacterial evasion.
• P2Y14R targeting alleviates platelet-induced NET formation and venous thrombosis, linking aggregation-related pathways to thrombosis.
• Neutrophil granule proteins can inhibit amyloid beta aggregation and neurotoxicity, suggesting broader roles in neurodegeneration.
• Neutrophil extracellular trap-driven occlusive diseases highlight the pathological consequences of dysregulated aggregation.
• Lymphokine-induced neutrophil aggregation was recognized decades ago, indicating a long-standing research interest.
• CRISPR-based models are needed to causally link specific genes to neutrophil aggregation phenotypes [1,3,4].
What Happens During neutrophil aggregation?
Initiation by cytokines and pathogen-derived factors
In simple terms: Neutrophils start sticking to each other when they receive signals from cytokines or pathogens.
Neutrophil aggregation can be initiated by lymphokines, as shown in early studies where lymphokine-induced neutrophil aggregation was characterized. More recently, mesenchymal stromal cells were found to induce neutrophil aggregation and extracellular vesicle storms in systemic lupus erythematosus. Pathogen-derived factors, such as Staphylococcus aureus SaeR/S-regulated factors, can overcome complement-mediated inhibition of aggregation, leading to enhanced aggregation and evasion of neutrophil killing. These triggers activate signaling pathways that upregulate adhesion molecules on the neutrophil surface, promoting homotypic adhesion [1,7].
Adhesion molecule engagement and homotypic binding
In simple terms: Specific adhesion molecules on the neutrophil surface bind to each other, linking neutrophils together.
The core of neutrophil aggregation is the engagement of adhesion molecules between adjacent neutrophils. While the exact adhesion molecules may vary by context, the process requires cell surface receptors that mediate homotypic binding. Complement regulators can inhibit this step, as seen with human complement-mediated inhibition of aggregation, which Staphylococcus aureus can overcome. The QuickGO definition explicitly states that aggregation occurs via adhesion molecules, underscoring their central role.
Formation of neutrophil clusters and swarming
In simple terms: Neutrophils form clusters that can grow into swarms, amplifying the local immune response.
Aggregation leads to the formation of neutrophil clusters, a process often referred to as swarming. Type I interferon signaling inhibits neutrophil swarming, thereby promoting intracellular bacterial evasion. This suggests that swarming is a regulated process that can be modulated by host cytokines. The clustered neutrophils can then release extracellular vesicles and form neutrophil extracellular traps, further influencing the inflammatory milieu [1,8].
Release of extracellular vesicles and extracellular traps
In simple terms: Aggregated neutrophils release vesicles and web-like traps that can degrade inflammatory signals.
Aggregated neutrophils can release extracellular vesicle storms, as observed in systemic lupus erythematosus, which may contribute to disease pathogenesis. Additionally, aggregated neutrophil extracellular traps can degrade cytokines and chemokines, thereby limiting inflammation. This dual role highlights the complexity of aggregation: it can both amplify and resolve inflammation depending on context [1,8].
Resolution or pathological persistence
In simple terms: Aggregation can either help resolve inflammation or, if dysregulated, contribute to disease.
Under normal conditions, aggregated neutrophil extracellular traps degrade pro-inflammatory mediators, promoting resolution. However, dysregulated aggregation is associated with occlusive diseases and thrombosis [3,6]. For example, targeting P2Y14R alleviates platelet-induced NET formation and venous thrombosis through the PKA/AKAP13/RhoA axis, linking aggregation-related pathways to thrombotic pathology. Thus, the balance between beneficial and pathological aggregation is critical [3,6,8].
Key Genes Involved in GO:0070488 neutrophil aggregation
The following genes and proteins have been implicated in neutrophil aggregation or related processes based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| P2RY14 (P2Y14R) | Purinergic receptor involved in platelet-induced NET formation and venous thrombosis | Target for alleviating thrombosis; linked to aggregation-related pathways |
| AKAP13 | Scaffolding protein in PKA/RhoA signaling axis | Mediates P2Y14R effects on NET formation |
| RHOA | Small GTPase regulating cytoskeletal dynamics | Downstream of P2Y14R in NET formation |
| PRKACA (PKA) | Protein kinase A | Component of P2Y14R signaling axis |
| C5 | Complement component | Complement-mediated inhibition of aggregation can be overcome by S. aureus |
| C3 | Complement component | Involved in complement-mediated inhibition of aggregation |
| SaeR/S | Staphylococcus aureus regulatory system | Regulates factors that overcome complement inhibition of aggregation |
| IFNAR1 | Type I interferon receptor | Type I interferon signaling inhibits neutrophil swarming |
| IFNAR2 | Type I interferon receptor | Type I interferon signaling inhibits neutrophil swarming |
| ITGAM (CD11b) | Integrin alpha M, adhesion molecule | Potential mediator of homotypic adhesion |
| ITGB2 (CD18) | Integrin beta 2, adhesion molecule | Potential mediator of homotypic adhesion |
| SELPLG (PSGL-1) | Selectin ligand | Potential adhesion molecule in aggregation |
| CXCR2 | Chemokine receptor | May influence neutrophil recruitment and aggregation |
| FCGR2A | Fc gamma receptor | Immune complex recognition may trigger aggregation |
| ELANE | Neutrophil elastase | Granule protein; may influence aggregation and NET formation |
| MPO | Myeloperoxidase | Granule protein; involved in NET formation |
| AZU1 | Azurocidin | Granule protein with antimicrobial activity |
| DEFA3 | Defensin alpha 3 | Granule protein; may modulate aggregation |
How Is neutrophil aggregation Regulated?
Neutrophil aggregation is regulated by multiple signaling pathways. Type I interferon signaling inhibits neutrophil swarming, thereby limiting aggregation and promoting intracellular bacterial evasion. Complement regulators can inhibit aggregation, but pathogens such as Staphylococcus aureus can overcome this inhibition through SaeR/S-regulated factors. The P2Y14R/PKA/AKAP13/RhoA axis modulates platelet-induced NET formation, which is closely linked to aggregation-related processes. Additionally, aggregated neutrophil extracellular traps can degrade cytokines and chemokines, providing a negative feedback loop that limits inflammation. These regulatory mechanisms highlight the balance between pro-aggregatory and anti-aggregatory signals [3,4,7,8].
neutrophil aggregation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| P2RY14 | Venous thrombosis | Knockout mouse or human neutrophil-like cells with P2RY14 KO |
| IFNAR1 | Intracellular bacterial evasion | Knockout mice or CRISPR KO in neutrophils |
| C5 | Staphylococcus aureus evasion | Knockout or knock-in of complement regulators |
| ELANE | Neurodegeneration | Overexpression or KO in neutrophil-like cells |
| MPO | Occlusive diseases | Knockout mouse models |
Systemic lupus erythematosus
In systemic lupus erythematosus, mesenchymal stromal cells induce neutrophil aggregation and extracellular vesicle storms, which may contribute to disease pathogenesis. This suggests that targeting neutrophil aggregation could be a therapeutic strategy in lupus.
Venous thrombosis and occlusive diseases
P2Y14R targeting alleviates platelet-induced NET formation and venous thrombosis through the PKA/AKAP13/RhoA axis, linking aggregation-related pathways to thrombotic disorders. Neutrophil extracellular trap-driven occlusive diseases further underscore the pathological role of dysregulated aggregation.
Bacterial evasion and infection
Staphylococcus aureus SaeR/S-regulated factors overcome human complement-mediated inhibition of aggregation to evade neutrophil killing. Type I interferon signaling inhibits neutrophil swarming, promoting intracellular bacterial evasion. These findings highlight the importance of aggregation in host-pathogen interactions [4,7].
Neurodegeneration
Neutrophil granule proteins inhibit amyloid beta aggregation and neurotoxicity, suggesting a potential link between neutrophil-derived factors and Alzheimer's disease pathology. While this is not directly about neutrophil aggregation, it indicates broader roles for neutrophil granule proteins in neurodegeneration.
From neutrophil aggregation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does P2RY14 mediate neutrophil aggregation? | P2RY14 knockout in human neutrophil-like HL-60 cells or mouse neutrophils |
| Does type I interferon signaling inhibit aggregation? | IFNAR1/2 knockout mice or CRISPR KO in neutrophils |
| Can S. aureus overcome complement inhibition? | Complement C5 knockout or knock-in models |
| What is the role of granule proteins in aggregation? | ELANE, MPO, or DEFA3 knockout or overexpression in neutrophil-like cells |
| Does aggregated NET degradation limit inflammation? | Knock-in of tagged NET components for imaging |
| Can mesenchymal stromal cells induce aggregation? | Co-culture with CRISPR-edited neutrophils |
How to Study the neutrophil aggregation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Light transmission aggregometry | Neutrophil aggregation in suspension | Testing triggers and inhibitors |
| Flow cytometry | Cluster formation and surface marker expression | Quantifying aggregation and adhesion molecules |
| Live-cell imaging | Dynamics of neutrophil swarming | Visualizing aggregation in real time |
| Nanoparticle tracking analysis | Extracellular vesicle release | Assessing vesicle storms from aggregated neutrophils |
| Immunofluorescence | NET formation and colocalization | Detecting aggregated NETs |
| CRISPR knockout screen | Gene requirement for aggregation | Identifying novel regulators [1,3,4] |
| Proteomics | Protein composition of aggregates | Discovering adhesion molecules |
| RNA-seq | Transcriptional changes during aggregation | Identifying signaling pathways |
In vitro aggregation assays
Neutrophil aggregation can be measured using light transmission aggregometry or flow cytometry-based assays, where the formation of neutrophil clusters is quantified [2,7]. These assays are useful for testing the effects of cytokines, pathogens, or genetic perturbations [2,7].
Imaging of neutrophil swarms
Live-cell imaging and confocal microscopy can visualize neutrophil swarming and aggregation in real time. This approach allows researchers to track the dynamics of cluster formation and the involvement of specific adhesion molecules.
Extracellular vesicle and NET analysis
Aggregated neutrophils release extracellular vesicles and neutrophil extracellular traps, which can be analyzed by nanoparticle tracking, electron microscopy, or immunofluorescence for NET markers [1,8]. These methods help link aggregation to downstream effector functions [1,8].
CRISPR-based genetic screens
CRISPR knockout screens in neutrophil-like cell lines can identify genes required for aggregation [1,3,4]. Such screens enable unbiased discovery of adhesion molecules and signaling pathways [1,3,4].
How CRISPR Can Be Used to Study GO:0070488 neutrophil aggregation
Knockout
CRISPR knockout of candidate genes such as P2RY14, IFNAR1, or complement components in neutrophil-like cells or primary neutrophils can test their requirement for aggregation [3,4,7]. Knockout models are essential for establishing causality [1,3,4].
Point Mutation
Point mutations can be introduced to mimic disease-associated variants or to disrupt specific domains of adhesion molecules, allowing fine mapping of aggregation mechanisms [1,3].
Knock-in
Knock-in of tagged adhesion molecules or signaling proteins enables live-cell imaging and proteomic analysis of aggregation complexes [1,8].
Overexpression
Overexpression of candidate genes such as ELANE or MPO can test sufficiency for inducing aggregation or related phenotypes.
How EDITGENE Supports neutrophil aggregation Research
Researchers studying neutrophil aggregation-related genes often need to determine whether a candidate gene is causally involved in the process or merely correlated with it. This requires precise genetic models that can knockout, mutate, knock-in, or overexpress the gene of interest in relevant neutrophil backgrounds. EDITGENE provides a comprehensive suite of CRISPR services to accelerate such studies.
Contact EDITGENE today to design your custom CRISPR model for neutrophil aggregation research.
Frequently Asked Questions About neutrophil aggregation
What is neutrophil aggregation?
Neutrophil aggregation (GO:0070488) is the adhesion of one neutrophil to one or more other neutrophils via adhesion molecules.
What genes are involved in neutrophil aggregation?
Genes such as P2RY14, AKAP13, RHOA, IFNAR1, C5, and ELANE have been implicated in neutrophil aggregation or related processes [3,4,5,7].
How is neutrophil aggregation measured?
It can be measured by light transmission aggregometry, flow cytometry, or live-cell imaging of neutrophil swarms [2,4,7].
What diseases are associated with neutrophil aggregation?
Systemic lupus erythematosus, venous thrombosis, occlusive diseases, and bacterial infections have been linked to neutrophil aggregation [1,3,4,6,7].
Does type I interferon affect neutrophil aggregation?
Yes, type I interferon signaling inhibits neutrophil swarming, thereby limiting aggregation.
What is the role of P2Y14R in neutrophil aggregation?
P2Y14R is involved in platelet-induced NET formation and venous thrombosis through the PKA/AKAP13/RhoA axis, which is related to aggregation processes.
Can Staphylococcus aureus evade neutrophil aggregation?
Yes, S. aureus SaeR/S-regulated factors overcome human complement-mediated inhibition of aggregation to evade neutrophil killing.
What are aggregated neutrophil extracellular traps?
They are web-like structures released by aggregated neutrophils that can degrade cytokines and chemokines, limiting inflammation.
How can CRISPR help study neutrophil aggregation?
CRISPR knockout, knock-in, and overexpression models allow causal testing of candidate genes in neutrophil aggregation [1,3,4].
What cell models are used for neutrophil aggregation research?
Human neutrophil-like HL-60 cells, primary neutrophils, and mouse models are commonly used [1,3,4].
Conclusion
Neutrophil aggregation (GO:0070488) is a fundamental biological process with important roles in immunity, inflammation, and disease. The adhesion of neutrophils to one another via adhesion molecules triggers downstream events such as extracellular vesicle release and NET formation, which can either resolve or exacerbate pathology [1,8]. Dysregulated aggregation is implicated in systemic lupus erythematosus, thrombosis, and bacterial evasion [1,3,4,7]. Continued research using CRISPR-based genetic models will be essential to dissect the molecular mechanisms and to identify therapeutic targets [1,3,4].
References
- 1. Ou Q et al.. 2025. Mesenchymal stromal cells induce neutrophil aggregation and extracellular vesicle storms for systemic lupus erythematosus.. Signal Transduct Target Ther 10(1):344 PMID: 41083438
- 2. Badenoch-Jones P. 1982. Lymphokine-induced neutrophil aggregation.. Immunology 47(1):169-74 PMID: 7118158
- 3. Fang Y et al.. 2026. Targeting P2Y14R alleviates platelet-induced NET formation and venous thrombosis through PKA/AKAP13/RhoA axis.. Eur Heart J 47(16):1982-1997 PMID: 41143464
- 4. Li S et al.. 2024. Inhibition of neutrophil swarming by type I interferon promotes intracellular bacterial evasion.. Nat Commun 15(1):8663 PMID: 39375351
- 5. Kasus-Jacobi A et al.. 2021. Neutrophil Granule Proteins Inhibit Amyloid Beta Aggregation and Neurotoxicity.. Curr Alzheimer Res 18(5):414-427 PMID: 34429047
- 6. Yaykasli KO et al.. 2021. Neutrophil Extracellular Trap-Driven Occlusive Diseases.. Cells 10(9) PMID: 34571857
- 7. Pettygrove BA et al.. 2025. Staphylococcus aureus SaeR/S-regulated factors overcome human complement-mediated inhibition of aggregation to evade neutrophil killing.. Proc Natl Acad Sci U S A 122(20):e2412447122 PMID: 40359050
- 8. Schauer C et al.. 2014. Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines.. Nat Med 20(5):511-7 PMID: 24784231
